Levetiracetam Tablet
Product Images NDC 87063-192

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 87063-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000 (Label 1000mg)

Labels for Levetiracetam Tablets, USP 1000 mg oral tablets, packaged by Enovachem Pharmaceuticals with NDC 87063-193-30, 87063-193-90, and relabeled with NDC 87063-193-60. Labels include package quantity options of 30, 90, and 60 tablets, manufacturer Cranbury Pharmaceuticals, LLC, and contain barcode and batch information. They also note storage instructions and a federal law caution.*

FDA Label Image

250 (Label 250mg)

Packaging labels for Levetiracetam Tablets, USP 250 mg, supplied by Enovachem Pharmaceuticals. Each label indicates different package sizes including quantities of 30, 60, 90, and 120 tablets. The labels show labeler and manufacturer information, NDC codes, batch numbers, expiration dates, and storage instructions. The tablets are described as blue/oval with a scored and film-coated/debossed finish.*

FDA Label Image

500 (Label 500mg)

Levetiracetam Tablets USP 500 mg packaging labels from Enovachem Pharmaceuticals, each showing different package quantities: 30, 60, 90, and 120 tablets. The labels include NDC numbers, manufacturer details (Cranbury Pharmaceuticals, LLC), storage instructions, and QR codes. Labels indicate the tablets are green, oval, scored, film-coated, and debossed.*

FDA Label Image

750 (Label 750mg)

Labels for Levetiracetam Tablets, USP 750 mg oral tablets, packaged by Enovachem Pharmaceuticals. Four labels show package quantities of 30, 60, 90, and 120 tablets, with NDC codes 87063-192-30, 87063-192-60, 87063-192-90, and 87063-192-12 respectively. Each label includes manufacturer and storage information, batch and lot details, barcodes, and a note that these are prescription drugs.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of levetiracetam, showing the arrangement of atoms including a pyrrolidone ring with distinct bonds and functional groups typical for the molecule.*

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

A bar chart comparing the percentage of patients among three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%). The y-axis represents the percentage of patients, ranging from 0% to 45%, highlighting differences in patient response rates for each treatment group.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar chart showing the percentage of patients for three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart displays patient percentages on the vertical axis, with Levetiracetam 2000 mg/day having the highest percentage at 35.2%, followed by Levetiracetam 1000 mg/day at 20.8%, and Placebo at 6.3%.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar chart comparing the percentage of patients between two groups: Placebo and Levetiracetam 3000 mg/day. The vertical axis shows percentage of patients, with the Levetiracetam group showing a higher value around 39.4% and the Placebo group around 14.4%. The sample sizes for each group are noted below the respective bars.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar graph comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The Levetiracetam group shows a higher percentage (44.6%) compared to the Placebo group (19.6%), with an asterisk indicating statistical significance.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The chart shows approximately 19.6% for Placebo and 43.1% for Levetiracetam, indicating a higher patient response with Levetiracetam.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A bar graph comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The vertical axis represents the percentage of patients from 0% to 100%. The Levetiracetam group shows a higher percentage (72.2%) compared to the Placebo group (45.2%).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.